
    
      The purpose of this study is to determine whether nilotinib is effective in the prophylaxis
      and treatment of CMV reactivation in allo-HSCT patients.

      Prophylaxis Part: patients will be treated with nilotinib after their hemogram engraftment to
      prevent CMV reactivation Salvage Part: patients who have had intractable CMV reactivation
      after gancyclovir therapy will be treated with nilotinib
    
  